Document is current
Any future updates will be listed below
-
Authors
Zhang, Shihong
Tang, Tzu-Hao https://orcid.org/0009-0009-2596-1872
Kinsella, Sinéad
Mazziotta, Francesco
Schweizer, Michael T.
McAfee, Megan S.
Munkhbat, Ariunaa
Su, Yapeng
Voillet, Valentin https://orcid.org/0000-0002-5751-3881
Martin, Lauren E.
Smith, Colton W. https://orcid.org/0000-0003-3669-8327
Asano, Yuta
Hailemariam, Menna
Bakhtiari, Jakob
Lee, Bo
Yeung, Cecilia https://orcid.org/0000-0001-6799-2022
Chen, Hung https://orcid.org/0000-0001-5119-6208
Rizzi, Alessandro M. https://orcid.org/0009-0001-1963-0884
Chen, Daniel G. https://orcid.org/0000-0001-6660-6257
Furiya, Kelsey
Horst, Nick
Zhang, Tianzi
Le, Phung
McKenna, Kelly
Oda, Shannon K.
Rongvaux, Anthony https://orcid.org/0000-0001-7142-6533
Greenberg, Phillip D. https://orcid.org/0000-0003-3812-647X
Schmitt, Thomas M. https://orcid.org/0000-0002-0736-4195
Chapuis, Aude G. https://orcid.org/0000-0002-9574-5448
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P01CA225517)
U.S. Department of Health & Human Services | National Institutes of Health (P01CA18029-41)
Emmerson Collective, Immunotherapy Integrated Research Center Fred Hutchinson Cancer Center, Elevate Bio
- License Information
-
More Information
Article History
Received: 24 February 2025
Accepted: 2 December 2025
First Online: 3 January 2026
Competing interests
: A.G.C. has received support from Elevate Bio, Juno Therapeutics, Lonza, and Affini-T. P.D.G. is on the Scientific Advisory Board of Celsius, Earli, Elpiscience, Immunoscape, Rapt, and Nextech, was a scientific founder of Juno Therapeutics, and receives research support from Lonza. A.G.C., T.M.S., and P.D.G. are co-founders of, have equity in, and receive research support from Affini-T. A.G.C., T.M.S., and M.M. are listed as inventors on patents related to MA1 TCR and CD8/28 constructs. The remaining authors declare no competing interests.
